Type 1 Diabetes
18 articles on Type 1 Diabetes, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic, Wegovy, Mounjaro: How Do They Affect Mental Health?
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
7 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.
8 min read
Beyond Weight Loss: Surprising Health Benefits of GLP-1 Drugs
While widely recognized for their effectiveness in weight management, GLP-1 receptor agonists are revealing a spectrum of profound health benefits. Discover how these groundbreaking medications are impacting cardiovascular health, kidney function, liver disease, and even potentially neurodegenerative conditions.
7 min read
Understanding Insulin Resistance: Beyond Blood Sugar
Insulin resistance is a critical metabolic condition affecting blood sugar regulation and potentially impacting brain function. This comprehensive guide delves into its causes, symptoms, and the vital role of lifestyle interventions.
8 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.
4 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
4 min read
India Issues Guidelines on GLP-1 Drugs Use, Risks, Regulations
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
6 min read
Telangana Warns on Semaglutide Misuse for Weight Loss
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
5 min read
Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide in India
Indian pharma leaders Sun Pharma, Dr Reddy's, and Glenmark have launched generic semaglutide injections in India, slashing costs compared to Ozempic and Wegovy after patent expiry. With weekly prices starting at Rs 325, these options make GLP-1 therapy accessible for type 2 diabetes and weight management. Zydus joins with more affordable brands, transforming treatment affordability.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
Abbott Partners with Novo for Semaglutide Extensior in India
Abbott has tied up with Novo Nordisk India to commercialize Extensior, the second brand of semaglutide injection following Ozempic's launch. This move positions Abbott as the second firm with sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. With demand surging and generics on the horizon, here's what it means for patients.
4 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read
Lost 32% Body Weight on Mounjaro: Mistakes to Avoid
A woman known as @cartcrushuk on TikTok dropped 32% of her body weight using Mounjaro fat jabs and is now sharing the 'Mounjaro mistakes' she made along the way. From wasting time before starting to struggling with hydration and before photos, her honest advice focuses on protein, fiber, and basics for success. Her video has inspired thousands with nearly 15,000 views in four days.
5 min read
Super Bowl LX Ads Feature AI, GLP-1 Drugs & Celebs from Clooney to Jenner
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
6 min read
Oral Wegovy: Benefits, Dosing, and What Patients Need to Know
Novo Nordisk's oral Wegovy has launched with impressive prescription volumes, offering a pill alternative to injections for weight management. Learn about its efficacy, ideal candidates, dosing, and how it fits into GLP-1 therapy. This guide breaks down the science and practical advice for patients.
5 min read
GLP-1 Drugs Reduce Mortality Risk in Type 1 Diabetes
A recent study indicates that GLP-1 receptor agonists and incretin-based drugs may decrease mortality risk and hospital visits for adults with type 1 diabetes. Researchers compared outcomes in users versus non-users, finding significant benefits across BMI categories. Further long-term studies are needed to confirm safety and efficacy.
3 min read